🔎 Trials Near Me

Home › Ewing Sarcoma › District of Columbia › Washington

Ewing Sarcoma clinical trials in Washington, DC

6 studies for Ewing Sarcoma are looking for participants at sites in and around Washington (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

RecruitingPhase 1/2
  • Children's National Medical Center, Washington D.C.
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119

Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

RecruitingPhase 1
  • Children's National Hospital, Washington D.C.
  • Childrens National Hospital, Washington D.C.
Ages 1 to 23 · All sexes · Updated Aug 13, 2026 · NCT07172958

Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma

Recruiting
  • Sibley Memorial Hospital, Washington D.C.
Up to age 39 · All sexes · Updated Jul 13, 2026 · NCT06796543

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

RecruitingPhase 1/2
  • Children's National Medical Center, Washington D.C.
12 Months – 30 Years · All sexes · Updated May 19, 2026 · NCT04901702

Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

RecruitingPhase 1/2
  • Children's National Hospital, Washington D.C.
Ages 2 to 30 · All sexes · Updated Feb 3, 2026 · NCT05734066

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

RecruitingPhase 2
  • Children's National Medical Center, Washington D.C.
18 Months – 40 Years · All sexes · Updated Aug 12, 2025 · NCT05135975

Ewing Sarcoma trials in other cities

Other studies in Washington

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.